Examiner: OLSON, ANDREA STEFFEL

Tech Center 3700 • Art Units: 1623 1656 1673 1693 3762

This examiner grants 62% of resolved cases

Performance Statistics

62.2%

Allow Rate

-7.8% vs TC avg

1,472

Total Applications

-12.0%

Interview Lift

1153

Avg Prosecution Days

Based on 1418 resolved cases, 2023–2026

3.0%

§101 Eligibility

17.4%

§102 Novelty

37.6%

§103 Obviousness

23.0%

§112 Clarity

App #	Title	Status	Assignee
17584129	METHODS AND THERAPIES FOR TREATING ATHEROSCLEROSIS AND/OR HYPERLIPIDEMIA USING OLIGOSACCHARIDES	Final Rejection	The Regents of the University of California
18883520	TARGETED COMPOSITIONS	Final Rejection	ARBUTUS BIOPHARMA CORPORATION
18409330	TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS	Final Rejection	ARBUTUS BIOPHARMA CORPORATION

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.